JP2620333B2 - 抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤 - Google Patents
抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤Info
- Publication number
- JP2620333B2 JP2620333B2 JP63241207A JP24120788A JP2620333B2 JP 2620333 B2 JP2620333 B2 JP 2620333B2 JP 63241207 A JP63241207 A JP 63241207A JP 24120788 A JP24120788 A JP 24120788A JP 2620333 B2 JP2620333 B2 JP 2620333B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- antigestagen
- methyl
- abortion
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 230000001833 anti-estrogenic effect Effects 0.000 title claims abstract description 32
- 239000003418 antiprogestin Substances 0.000 title claims description 34
- 239000003814 drug Substances 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title claims description 5
- 208000005171 Dysmenorrhea Diseases 0.000 title claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims description 3
- 201000009273 Endometriosis Diseases 0.000 title claims description 3
- 206010000210 abortion Diseases 0.000 title description 13
- 231100000176 abortion Toxicity 0.000 title description 13
- 230000006698 induction Effects 0.000 title description 8
- 230000000380 anti-gestagenic effect Effects 0.000 title description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 29
- 230000035935 pregnancy Effects 0.000 claims description 16
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 15
- 229940046836 anti-estrogen Drugs 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 12
- 229960001603 tamoxifen Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001911 anti-progestational effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 208000037805 labour Diseases 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 241000700198 Cavia Species 0.000 description 6
- 239000003886 aromatase inhibitor Substances 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 239000000044 progesterone antagonist Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940005186 tamoxifen 10 mg Drugs 0.000 description 3
- -1 4-dimethylaminophenyl Chemical group 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- DKVSUQWCZQBWCP-QAGGRKNESA-N androsta-1,4,6-triene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 DKVSUQWCZQBWCP-QAGGRKNESA-N 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940077150 progesterone and estrogen Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- INJBMNNLSBCVGV-QDWSJHPCSA-N (8r,9r,10s,13r)-13-methyl-2,4,5,6,7,8,9,10,11,12-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]12)CC(=O)CC1CC[C@@H]1[C@@H]2CC[C@@]2(C)C1=CC=C2 INJBMNNLSBCVGV-QDWSJHPCSA-N 0.000 description 1
- YEWSFUFGMDJFFG-QAGGRKNESA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 YEWSFUFGMDJFFG-QAGGRKNESA-N 0.000 description 1
- RSPINGMAWKOXBT-BZGHQHJYSA-N (8r,9s,13s,14s,16s,17s)-16-ethyl-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 RSPINGMAWKOXBT-BZGHQHJYSA-N 0.000 description 1
- YEWSFUFGMDJFFG-UHFFFAOYSA-N (9beta,10alpha)-Androsta-4,6-diene-3,17-dione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3C=CC2=C1 YEWSFUFGMDJFFG-UHFFFAOYSA-N 0.000 description 1
- PJMNEPMSGCRSRC-IEVKOWOJSA-N 4-androstene-3,6,17-trione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=O)C2=C1 PJMNEPMSGCRSRC-IEVKOWOJSA-N 0.000 description 1
- OSVMTWJCGUFAOD-UHFFFAOYSA-N 4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1O OSVMTWJCGUFAOD-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 206010046809 Uterine pain Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873733478 DE3733478A1 (de) | 1987-10-01 | 1987-10-01 | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| DE3733478.6 | 1987-10-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01106823A JPH01106823A (ja) | 1989-04-24 |
| JP2620333B2 true JP2620333B2 (ja) | 1997-06-11 |
Family
ID=6337559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63241207A Expired - Fee Related JP2620333B2 (ja) | 1987-10-01 | 1988-09-28 | 抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤 |
| JP63241208A Expired - Fee Related JP2656958B2 (ja) | 1987-10-01 | 1988-09-28 | ホルモン依存性腫瘍治療剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63241208A Expired - Fee Related JP2656958B2 (ja) | 1987-10-01 | 1988-09-28 | ホルモン依存性腫瘍治療剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4888331A (OSRAM) |
| EP (1) | EP0310541B1 (OSRAM) |
| JP (2) | JP2620333B2 (OSRAM) |
| AT (2) | ATE106730T1 (OSRAM) |
| AU (2) | AU616208B2 (OSRAM) |
| CA (2) | CA1330039C (OSRAM) |
| DE (3) | DE3733478A1 (OSRAM) |
| DK (2) | DK550088A (OSRAM) |
| ES (2) | ES2055745T3 (OSRAM) |
| GR (1) | GR3007225T3 (OSRAM) |
| IE (2) | IE65165B1 (OSRAM) |
| IL (2) | IL87886A (OSRAM) |
| PH (1) | PH26774A (OSRAM) |
| ZA (2) | ZA887378B (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2654337B1 (fr) * | 1989-11-15 | 1994-08-05 | Roussel Uclaf | Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant. |
| DE4329344A1 (de) * | 1993-08-27 | 1995-03-02 | Schering Ag | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri |
| DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6399593B1 (en) * | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
| EP1173213A1 (en) * | 1999-05-04 | 2002-01-23 | American Home Products Corporation | Compositions containing benzimidazolones and progestogens |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
| US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| SI1173210T1 (en) * | 1999-05-04 | 2005-02-28 | Wyeth | Contraceptive compositions containing antiprogestinic and progestinic |
| US6380178B1 (en) * | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| ATE301129T1 (de) | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| JP2004510994A (ja) * | 2000-10-06 | 2004-04-08 | バイオメディシンズ，インコーポレイティド | エストロゲン−感受性疾病の処理のための組み合わせ治療 |
| DE60115274T2 (de) * | 2000-10-18 | 2006-07-27 | Schering Ag | Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen |
| US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20030013694A1 (en) * | 2001-05-25 | 2003-01-16 | Jens Hoffmann | Use and compositions of antiprogestins for treatment of prostate diseases |
| GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
| DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| EP1603563A4 (en) * | 2003-02-28 | 2007-08-22 | Morgan Lee R | RESONANCE MODULATOR FOR DIAGNOSIS AND THERAPY |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| US8685950B2 (en) * | 2004-10-04 | 2014-04-01 | Wayne State University | Use of aromatase inhibitors for treatment of ectopic pregnancy |
| WO2008019048A1 (en) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Use of aromatase inhibitors for thining the endometrium or treating menorrhagia |
| US7694688B2 (en) | 2007-01-05 | 2010-04-13 | Applied Materials, Inc. | Wet clean system design |
| WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
| US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| IL68222A (en) * | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
| DE3323321A1 (de) * | 1983-06-24 | 1985-01-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels |
| DE3337450A1 (de) * | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandine und antigestagene fuer den schwangerschaftsabbruch |
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
| US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| IE58836B1 (en) * | 1984-08-02 | 1993-11-17 | Labrie Fernand | Pharmaceutical composition for combination therapy of hormone dependent cancers |
| US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4732904A (en) * | 1984-12-24 | 1988-03-22 | Morgan Lee R | Antiestrogenic hydrazones |
| DE3533175A1 (de) * | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
| FR2598083B1 (fr) * | 1986-05-05 | 1989-12-29 | Theramex Laboratoire | Nouvelles compositions pharmaceutiques a action antiprogesteronique et leur procede d'obtention |
| DE3633244A1 (de) * | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
-
1987
- 1987-10-01 DE DE19873733478 patent/DE3733478A1/de not_active Withdrawn
-
1988
- 1988-09-28 JP JP63241207A patent/JP2620333B2/ja not_active Expired - Fee Related
- 1988-09-28 JP JP63241208A patent/JP2656958B2/ja not_active Expired - Fee Related
- 1988-09-30 DE DE3850026T patent/DE3850026D1/de not_active Expired - Lifetime
- 1988-09-30 CA CA000579022A patent/CA1330039C/en not_active Expired - Fee Related
- 1988-09-30 AU AU23322/88A patent/AU616208B2/en not_active Ceased
- 1988-09-30 IL IL87886A patent/IL87886A/xx active Protection Beyond IP Right Term
- 1988-09-30 AT AT88730222T patent/ATE106730T1/de not_active IP Right Cessation
- 1988-09-30 IE IE295388A patent/IE65165B1/en not_active IP Right Cessation
- 1988-09-30 ZA ZA887378A patent/ZA887378B/xx unknown
- 1988-09-30 AT AT88730221T patent/ATE83149T1/de not_active IP Right Cessation
- 1988-09-30 IE IE295488A patent/IE66335B1/en not_active IP Right Cessation
- 1988-09-30 DK DK550088A patent/DK550088A/da not_active Application Discontinuation
- 1988-09-30 ZA ZA887379A patent/ZA887379B/xx unknown
- 1988-09-30 IL IL87885A patent/IL87885A/xx active Protection Beyond IP Right Term
- 1988-09-30 DK DK550188A patent/DK550188A/da not_active Application Discontinuation
- 1988-09-30 DE DE8888730221T patent/DE3876582D1/de not_active Expired - Lifetime
- 1988-09-30 ES ES88730222T patent/ES2055745T3/es not_active Expired - Lifetime
- 1988-09-30 AU AU23321/88A patent/AU624082B2/en not_active Ceased
- 1988-09-30 EP EP88730221A patent/EP0310541B1/de not_active Expired - Lifetime
- 1988-09-30 PH PH37621A patent/PH26774A/en unknown
- 1988-09-30 ES ES88730221T patent/ES2053795T3/es not_active Expired - Lifetime
- 1988-09-30 CA CA000579023A patent/CA1329126C/en not_active Expired - Fee Related
- 1988-10-03 US US07/252,299 patent/US4888331A/en not_active Expired - Lifetime
-
1993
- 1993-03-05 GR GR920402867T patent/GR3007225T3/el unknown
-
1994
- 1994-02-14 US US08/195,046 patent/US5733902A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2620333B2 (ja) | 抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤 | |
| CN1124848C (zh) | 含有竞争性黄体酮拮抗和孕激素的复合物用于制备治疗子宫内膜异位或子宫平滑肌瘤的药 | |
| JP2002541126A (ja) | 低用量エストロゲン断続的ホルモン補充療法 | |
| BG62384B1 (bg) | Прогестероново-антагонистични и антиестрогенови активнисъединения с общо приложение за женски контрацептиви | |
| PT646008E (pt) | Minimizacao de hemorragias secundarias associadas a progestina | |
| US20050064031A1 (en) | Combination contraceptive, kits that contain the latter, and a method that uses the latter | |
| JPS61143319A (ja) | 分娩誘発又は妊娠中絶のための併用組合わせ組成物 | |
| BG62877B1 (bg) | Метод за контрол на женски фертилитет | |
| US20050171071A1 (en) | Menstrual cycle control and improvement of conception rates in females | |
| JP2582088B2 (ja) | 子宮でのプロスタグランジン合成抑制剤 | |
| BG106441A (bg) | Мезопрогестини (модулатори на прогестероновия рецептор) като компоненти на женски контрацептиви | |
| US5795881A (en) | Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type | |
| JP2716461B2 (ja) | プロゲステロン合成阻害剤及び抗ゲスタゲンを含有する医薬及びその製法 | |
| JP2636914B2 (ja) | 頚部軟化作用を有する医薬 | |
| WO1995005828A1 (de) | PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI) | |
| KR100729311B1 (ko) | 호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질) | |
| Anita et al. | Use of Progestogens in Clinical Practice of Obstetrics and Gynecology | |
| JPH0764743B2 (ja) | 分娩誘導用組合わせ組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |